enicepatide vs NNC0519-0130

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: GLP-1/GIP receptor (dual) · full Obesity pipeline

enicepatide

Developed by Roche and partners

Phase 3 in Obesitypeptide
Reliable signal

NCT06525935 · Phase 2 · completed

This was a randomized, double-blind, placebo-controlled Phase 2 trial in 469 adults with obesity and at least one weight-related condition. Enicepatide 24 mg produced significantly greater weight loss than placebo at week 48, 22.5% placebo-adjusted by one analysis method and 18.3% by another, both p<0.001, meeting the trial primary comparison.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: November 2027 · NCT07589686 (registry estimate)

Reported efficacy

Percent Change in Body Weight from Baseline to Week 48: Placebo-adjusted weight loss at Week 48 (efficacy estimand), 24 mg CT-388: 22.5% (p<0.001); treatment-regimen estimand: 18.3% (p<0.001) (met)

Result source: NCT06525935

NNC0519-0130

Developed by Novo Nordisk

Phase 2 in Obesitypeptide
Partial signal

NCT06326060 · Phase 2 · completed

The study was randomized and quadruple-blind, included placebo and active-comparator arms, and enrolled 354 participants; its primary endpoint was the clinical measure of relative body-weight change. Because the registry does not report whether this endpoint was met, the findings cannot currently support the highest evidence grade.

No aligned efficacy figure on record for this race.

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointenicepatideNNC0519-0130
Body weight, % change—Trial running · NCT07670416—Not reported
Weight loss of 5% or more—Trial running · NCT07670416—Not reported
Weight loss of 10% or more—Trial running · NCT07670416—Not reported
Waist circumference, change (cm)—Trial running · NCT07670416—Not reported

Body weight, % change

enicepatide
—Trial running · NCT07670416
NNC0519-0130
—Not reported

Weight loss of 5% or more

enicepatide
—Trial running · NCT07670416
NNC0519-0130
—Not reported

Weight loss of 10% or more

enicepatide
—Trial running · NCT07670416
NNC0519-0130
—Not reported

Waist circumference, change (cm)

enicepatide
—Trial running · NCT07670416
NNC0519-0130
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

NNC0519-0130: no structured comparison results are available for Obesity.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

enicepatide
Placebo-adjusted weight loss at Week 48 (efficacy estimand), 24 mg CT-388: 22.5% (p<0.001); treatment-regimen estimand: 18.3% (p<0.001) NCT06525935 · Phase 2 · design grade: strong · publication or press release

Type 2 Diabetes

Shared mechanism: GLP-1/GIP receptor (dual) · full Type 2 Diabetes pipeline

enicepatide

Developed by Roche and partners

Phase 3 in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: February 2028 · NCT07670416 (registry estimate)

No aligned efficacy figure on record for this race.

NNC0519-0130

Developed by Novo Nordisk

Phase 2 in Type 2 Diabetespeptide
Weak signal

NCT05363774 · Phase 1 · completed

This was a randomized, blinded, placebo-controlled study, a genuine controlled design, but it measured only safety and drug levels rather than a clinical efficacy outcome, and results have not been posted yet, so the evidence reflects the design only. Its registered primary outcome on ClinicalTrials.gov is "Number of treatment emergent adverse events (TEAE) in single ascending dose (SAD) part" (with 3 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointenicepatideNNC0519-0130
HbA1c, change—Trial running · NCT07889648—Not reported
Body weight, change (kg)—Trial running · NCT07889648—Not reported
HbA1c below 7%—Trial running · NCT07889648—Not reported
Fasting plasma glucose, change—Trial running · NCT07889648—Not reported
3-point MACE (% with event)—Trial running · NCT07889648—Not reported

HbA1c, change

enicepatide
—Trial running · NCT07889648
NNC0519-0130
—Not reported

Body weight, change (kg)

enicepatide
—Trial running · NCT07889648
NNC0519-0130
—Not reported

HbA1c below 7%

enicepatide
—Trial running · NCT07889648
NNC0519-0130
—Not reported

Fasting plasma glucose, change

enicepatide
—Trial running · NCT07889648
NNC0519-0130
—Not reported

3-point MACE (% with event)

enicepatide
—Trial running · NCT07889648
NNC0519-0130
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

enicepatide: no structured comparison results are available for Type 2 Diabetes.

NNC0519-0130: no structured comparison results are available for Type 2 Diabetes.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: enicepatide's landscape · NNC0519-0130's landscape